


Summary

Name	TNFSF10/TRAIL/APO-2L
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/µg as determined by LAL test.
Construction	Recombinant Human TNF-Related Apoptosis-Inducing Ligand is produced by our E.coli expression system and the target gene encoding Arg115-Gly281 is expressed.
Accession #	P50591
Host	E.coli
Species	Human
Predicted Molecular Mass	19.5 KDa
Formulation	Supplied as a 0.2 µm filtered solution of 40mM Tris-HCl, 300mM NaCl, 5%Trehalose, 5%Mannitol, 0.01%Tween80, 10%Glycerol, pH7.0.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at \leq -70°C, stable for 6 months after receipt. Store at \leq -70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	

SDS-PAGE image



Background

Alternative Names	Tumor Necrosis Factor Ligand Superfamily Member 10; Apo-2 Ligand; Apo-2L; TNF-Related Apoptosis-Inducing Ligand; Protein TRAIL; CD253; TNFSF10; APO2L;
Background	TRAIL Human TNFSF10 is a type II transmembrane protein with an intracellular N-

Product Name: Recombinant Human TRAIL Catalog #: PEH1698



terminus and a 'TNF homology domain' (THD) at the extracellular C terminus. TNFSF10 can interact with several distinct receptors. Two of these receptors that belongs to TNFR superfamily, DR4 (TRAIL-R1) and DR5 (TRAIL-R2/TRICK2), are plasma membrane proteins containing intracellular death domains essential for activating apoptosis. TNFSF10 is promising for cancer therapy because it is cytotoxic and activates apoptosis in the majority of malignant cells, but not in normal cells.

Note

For Research Use Only, Not for Diagnostic Use.